Overview
I am an Assistant Professor of Medical Oncology who primarily treats patients with colon cancer and gastroesophageal cancers, where I also conduct early phase immunotherapeutic trials. My laboratory and translational research are focused on tumor immune evasion and immunotherapy, particularly in the setting of metastasis. This work has led to a specific interest in tumor-mediated development of dendritic cell tolerance and suppressive myeloid populations. The ultimate goal of these studies is to create biomarker-directed immunotherapies for advanced gastrointestinal cancers.
Current Appointments & Affiliations
Assistant Professor of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2018 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Addressing Common Medications That Influence Immunotherapy Response in Solid Tumors.
Journal Article J Clin Oncol · March 2026 Full text Link to item CiteAbstract B041: GLP-1 receptor agonists associated with improved response to immune checkpoint inhibitors in solid tumors: a multi-institutional retrospective cohort study
Conference Cancer Immunology Research · February 18, 2026 AbstractIntroduction:Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly utilized for Type 2 Diabetes Mellitus ( ... Full text CiteAbstract C025: Effect of Chemotherapy on Spatial Relationships in the Colorectal Cancer Immune Microenvironment
Conference Cancer Immunology Research · February 18, 2026 AbstractMicrosatellite stable (MSS) stage IV colorectal cancer (CRC) is treated with chemotherapy (CT) and targeted therapy, but resistance is common, with only a 13% 5-year overall survival, and more eff ... Full text CiteRecent Grants
A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination with Atezolizumab Versus Fruquintinib in Patients with Advanced Microsatellite Stable Colorectal Cancer
Clinical TrialPrincipal Investigator · Awarded by Kahr Bio Australia Pty Ltd · 2026 - 2031A Phase1b/2, multicenter, randomized, open-label study to evaluate the efficacy and safety of GSK5764227 alone and in combination in participants with previously treated advanced unresectable or metastatic gastrointestinal solid tumors
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2025 - 2030A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator?s Choice of Adjuvant Chemotherapy in Participants with Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression (2138-CL-0102)
Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2025 - 2030View All Grants
Education
University of South Florida, College of Medicine ·
2012
M.D.